# US 2021/0196735 A1 · Synthetic composition for treating metabolic disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0196735 A1
- Document ID: US20210196735A1
- Status: Published application
- Kind: A1
- Application number: 17/141,772
- Filed: 2021-01-05
- Published: 2021-07-01
- Earliest claimed: 2014-12-08
- Assignees: Glycom A/S
- Applicants: Glycom A/S
- Inventors: Bruce McConnell; Louise Kristine Vigsnæs; Emma Elison
- Web page: https://patentgrep.com/patent/US20210196735A1

## CPC

- A61K 31/702: Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/0095: {Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006)}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method includes selecting a non-infant patient having an obesity-related metabolic disorder and being diagnosable with one or more of obesity, obesity-induced pre-diabetes, and obesity-induced type 2 diabetes. The method further includes selecting an effective amount of one or more human milk oligosaccharides (HMOs) selected from: fucosylated HMOs 2′-fucosyllactose (2′-FL), 3 -fucosyllactose (3-FL), lacto-N-fucopentaose I (LNFP-I), and difucosyllactose (DFL); non-fucosylated HMOs lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), 3′,6-di sialyllacto-N-tetraose (DSLNT), 6′-sialyllactose (6′-SL), and 3′-sialyllactose (3′-SL); and mixtures thereof. The method further includes increasing the relative abundance of Bifidobacterium adolescentis in the non-infant patient by administering the selected effective amount of the selected one or more HMOs and improving in the non-infant patient at least one condition selected from increased insulin sensitivity, reduced insulin resistance, improved gut barrier function, and reduction of metabolic inflammation. In various examples, the method includes increasing levels of at least one glucagon-like peptide.

## Claims

### Claim 1

A method comprising:
selecting a non-infant patient having an obesity-related metabolic disorder and being diagnosable with one or more of obesity, obesity-induced pre-diabetes, and obesity-induced type 2 diabetes;
selecting an effective amount of one or more human milk oligosaccharides (HMOs) selected from:
fucosylated HMOs 2′-fucosyllactose (2′-FL), 3-fucosyllactose (3-FL), difucosyllactose (DFL), and lacto-N-fucopentaose I (LNFP-I);
non-fucosylated HMOs lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), 3′,6-disialyllacto-N-tetraose (DSLNT), 6′-sialyllactose (6′-SL), and 3′-sialyllactose (3′-SL); and
mixtures thereof;
increasing the relative abundance of Bifidobacterium adolescentis in the non-infant patient by administering the selected effective amount of the selected one or more HMOs; and
improving in the non-infant patient at least one condition selected from increased insulin sensitivity, reduced insulin resistance, improved gut barrier function, and reduction of metabolic inflammation.

### Claim 2 (depends on 1)

The method of claim 1, wherein the one or more HMOs are synthetic HMOs.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the non-infant patient is an obese pediatric patient.

### Claim 4 (depends on 1)

The method of claim 1, wherein the effective amount of the HMOs is administered in a unit dosage form.

### Claim 5 (depends on 1)

The method of claim 1, wherein if the one or more selected HMOs include a mixture of fucosylated HMOs and non-fucosylated HMOs, the mass ratio of the fucosylated HMOs to the non-fucosylated HMOs in the mixture is from 5:1 to 2:1.

### Claim 6 (depends on 1)

The method of claim 1, wherein the effective amount of the one or more HMOs administered during an initial treatment period is from about 3 g to about 10 g per day.

### Claim 7 (depends on 1)

The method of claim 1, wherein the effective amount of the one or more HMOs administered during a maintenance treatment period is from about 1 g to about 5 g per day.

### Claim 8

A method comprising:
administering to a non-infant patient having an obesity-related metabolic disorder an effective amount of one to eight human milk oligosaccharides (HMOs) selected from:
fucosylated HMOs 2′-fucosyllactose (2′-FL), 3-fucosyllactose (3-FL), difucosyllactose (DFL),
non-fucosylated HMO selected from lacto-N-tetraose (LNT) and lacto-N-neotetraose (LNnT)
wherein the one to eight HMOs are administered in an amount effective to:
increase a relative abundance of Bifidobacterium adolescentis in the gastrointestinal microbiota of the non-infant patient; and
improve in the non-infant patient at least one condition selected from reduced metabolic endotoxemia, an improved level of a glucagon-like peptide, and reduction in an inflammatory marker associated with the metabolic disorder.

### Claim 9 (depends on 8)

The method of claim 8, wherein the one or more HMOs are synthetic HMOs.

### Claim 10 (depends on 8)

The method of claim 8, wherein the effective amount of the HMOs is administered in a unit dosage form.

### Claim 11 (depends on 8)

The method of claim 8, wherein if the one or more selected HMOs include a mixture of fucosylated HMOs and non-fucosylated HMOs, the mass ratio of the fucosylated HMOs to the non-fucosylated HMOs in the mixture is from 5:1 to 2:1.

### Claim 12 (depends on 8)

The method of claim 8, wherein the effective amount of the one or more HMOs administered during an initial treatment period is from about 3 g to about 10 g per day.

### Claim 13 (depends on 12)

The method of claim 12, wherein the effective amount of the one or more HMOs administered during a maintenance treatment period is from about 1 g to about 5 g per day.

### Claim 14

A method comprising:
selecting a non-infant human at risk of developing one or more conditions selected from obesity, obesity-induced pre-diabetes, and obesity-induced type 2 diabetes;
selecting an amount of one or more human milk oligosaccharides (HMOs) that is effective for increasing the relative abundance of Bifidobacterium adolescentis in the non-infant human, the HMOs selected from:
fucosylated HMOs 2′-fucosyllactose (2′-FL), 3-fucosyllactose (3-FL), difucosyllactose (DFL, lacto-N-fucopentaose I (LNFP-I), lacto-N-fucopentaose II (LNFP-II), lacto-N-fucopentaose III (LNFP- III), and lacto-N-fucopentaose V (LNFP-V) ;
non-fucosylated HMOs lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), 3′,6-disialyllacto-N-tetraose (DSLNT), 6′-sialyllactose (6′-SL), and 3′-sialyllactose (3′-SL); and
mixtures thereof; and
increasing the relative abundance of Bifidobacterium adolescentis in the non-infant human and reducing in the non-infant human the likelihood of the non-infant human developing the at least one condition selected from obesity, obesity-induced pre-diabetes, and obesity-induced type 2 diabetes by administering the selected effective amount of the selected one or more HMOs.

### Claim 15 (depends on 14)

The method of claim 14, further comprising reducing levels of lipopolysaccharide in the non-infant human by administering the selected effective amount of the selected one or more HMOs.

### Claim 16 (depends on 14)

The method of claim 14, further comprising improving in the non-infant human at least one condition selected from increased insulin sensitivity, reduced insulin resistance, improved gut barrier function, and reduction of metabolic inflammation by administering the selected effective amount of the one or more HMOs to the non-infant human.

### Claim 17 (depends on 14)

The method of claim 14, wherein the selected one or more HMOs are administered in a unit dosage form.

### Claim 18 (depends on 14)

The method of claim 14, wherein if the one or more selected HMOs include a mixture of fucosylated HMOs and non-fucosylated HMOs, the mass ratio of the fucosylated HMOs to the non-fucosylated HMOs in the mixture is from 5:1 to 2:1.

### Claim 19 (depends on 14)

The method of claim 14, wherein the effective amount of the one or more HMOs administered during an initial treatment period is from about 3 g to about 10 g per day.

### Claim 20 (depends on 12)

The method of claim 12, wherein the effective amount of the one or more HMOs administered during a maintenance treatment period is from about 1 g to about 5 g per day.
